Investigating a stock’s 52-week price history, covering the range of low and high prices, can provide significant information about its present state and future potential. Gain Therapeutics Inc’s current trading price is -45.77% away from its 52-week high, while its distance from the 52-week low is 82.11%. The stock’s price range during this period has varied between $0.95 and $3.19. The company, active in the Healthcare sector, saw a trading volume of around 1.74 million for the day, considerably higher average daily volume of 0.27 million observed over the last three months.
Gain Therapeutics Inc (GANX) currently has a stock price of $1.73. The stock saw a sharp increase in the last trading session, hitting a high of $12.0 after opening at $1.73. The lowest recorded price for the day was $5.0 before it closed at $1.54.
Gain Therapeutics Inc’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $3.19 on 10/17/24, and the lowest price during the same period was recorded at $0.95 on 09/03/24.
How Financial Performance Impacts Market Capitalization
Gain Therapeutics Inc (GANX) has experienced a quarterly decline of -4.42% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 62.19M and boasts a workforce of 25 employees.
Decoding Analysts’ Ratings for Gain Therapeutics Inc
As of right now, 4 analysts are rating Gain Therapeutics Inc as a BUY, 3 of the polled analysts branded the stock as an OVERWEIGHT, 0 analyst is recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.
The Role of Moving Averages and Trading Volume in Technical Analysis
Based on Barchart.com data, the company’s moving average over the 100-day period was 1.7798, with a change in price of -0.5900. Similarly, Gain Therapeutics Inc recorded 294,872 in trading volume during the last 100 days, posting a change of -25.43%.
How GANX’s Debt-to-Equity Ratio Affects Financial Health
A company’s financial condition and market reputation can be evaluated using the debt-to-equity (D/E) ratio. This ratio, calculated by dividing a company’s total liabilities by its shareholders’ equity, indicates the proportion of debt a company employs to back its assets in relation to its shareholders’ equity. At the time of writing, the total D/E ratio for GANX stands at 0.18. Similarly, the long-term debt-to-equity ratio is also 0.11.
GANX Stock Stochastic Average
As of today, the raw stochastic average of Gain Therapeutics Inc over the past 50 days is 45.07%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 45.07%. Additionally, the Stochastic %K and %D values for the company were 33.39% and 27.00%, respectively, over the past 20 days.
GANX Stock Price Performance Analysis
The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 84.81%.However, over the last six months, we can see a stronger performance of -32.42%. Over the last 30 days, the price of GANX has fallen by 7.45%. And in the last five days, it has surged by 16.89%.
